Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

OSTX

OS Therapies (OSTX)

OS Therapies Incorporated
일자:
정렬 기준:
 검색 관련기사 보기:AMEX:OSTX
일자시간출처헤드라인심볼기업
2024/11/1606:05Edgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
2024/11/1523:47Business WireOS Therapies Reports Third Quarter 2024 Financial Results and Provides Business UpdateAMEX:OSTXOS Therapies Incorporated
2024/11/1523:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:OSTXOS Therapies Incorporated
2024/11/1506:58Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBAMEX:OSTXOS Therapies Incorporated
2024/11/0421:00Business WireOS Therapies to Present at The Spartan Capital Investor ConferenceAMEX:OSTXOS Therapies Incorporated
2024/11/0206:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
2024/10/3021:51Business WireJoin OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30AMEX:OSTXOS Therapies Incorporated
2024/10/3005:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
2024/10/2905:55Edgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
2024/10/2905:44Business WireOS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of DirectorsAMEX:OSTXOS Therapies Incorporated
2024/10/2421:46Business WireOS Therapies to Present at the LD Micro Main Event XVIIAMEX:OSTXOS Therapies Incorporated
2024/10/1722:22Business WireOS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitAMEX:OSTXOS Therapies Incorporated
2024/10/0321:00Business WireOS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient VisitAMEX:OSTXOS Therapies Incorporated
2024/09/1321:09Business WireOS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic CandidatesAMEX:OSTXOS Therapies Incorporated
2024/09/0521:22Business WireOS Therapies to Present at H.C. Wainright 26th Annual Global Investment ConferenceAMEX:OSTXOS Therapies Incorporated
2024/08/2920:53Business WireOS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment DoseAMEX:OSTXOS Therapies Incorporated
2024/08/2221:00Business WireOS Therapies Appoints Borys Shor, PhD to ADC Advisory BoardAMEX:OSTXOS Therapies Incorporated
2024/08/2219:00Business WireOS Therapies Clarifies CUSIP of Common StockAMEX:OSTXOS Therapies Incorporated
2024/08/1921:30Business WireOS Therapies Accepted Into Johnson & Johnson Innovation - JLABSAMEX:OSTXOS Therapies Incorporated
2024/08/0221:55Business WireOS Therapies Forms Osteosarcoma Patient Advocacy Advisory BoardAMEX:OSTXOS Therapies Incorporated
2024/08/0122:19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
2024/08/0122:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
2024/08/0122:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
2024/08/0122:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
2024/08/0122:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
2024/08/0113:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:OSTXOS Therapies Incorporated
2024/08/0107:21Business WireOS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”AMEX:OSTXOS Therapies Incorporated
2024/07/3103:41Edgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingAMEX:OSTXOS Therapies Incorporated
2024/07/3103:29Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]AMEX:OSTXOS Therapies Incorporated
2024/07/2423:48Business WireOS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast CancerAMEX:OSTXOS Therapies Incorporated
 검색 관련기사 보기:AMEX:OSTX